The Functional Impact of Alternative Splicing in Cancer.

Alternative splicing changes are frequently observed in cancer and are starting to be recognized as important signatures for tumor progression and therapy. However, their functional impact and relevance to tumorigenesis remain mostly unknown. We carried out a systematic analysis to characterize the potential functional consequences of alternative splicing changes in thousands of tumor samples. This analysis revealed that a subset of alternative splicing changes affect protein domain families that are frequently mutated in tumors and potentially disrupt protein-protein interactions in cancer-related pathways. Moreover, there was a negative correlation between the number of these alternative splicing changes in a sample and the number of somatic mutations in drivers. We propose that a subset of the alternative splicing changes observed in tumors may represent independent oncogenic processes that could be relevant to explain the functional transformations in cancer, and some of them could potentially be considered alternative splicing drivers (AS drivers).

[1]  M. Warmuth,et al.  Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point. , 2015, Cell reports.

[2]  Fan Yang,et al.  Protein Domain-Level Landscape of Cancer-Type-Specific Somatic Mutations , 2015, PLoS Comput. Biol..

[3]  P. Jordan,et al.  Antagonistic SR proteins regulate alternative splicing of tumor-related Rac1b downstream of the PI3-kinase and Wnt pathways. , 2009, Human molecular genetics.

[4]  Baldomero Oliva,et al.  ArchDB 2014: structural classification of loops in proteins , 2013, Nucleic Acids Res..

[5]  David Tamborero,et al.  OncodriveROLE classifies cancer driver genes in loss of function and activating mode of action , 2014, Bioinform..

[6]  Matthew Fraser,et al.  InterProScan 5: genome-scale protein function classification , 2014, Bioinform..

[7]  Paul A. Bates,et al.  Global topological features of cancer proteins in the human interactome , 2006, Bioinform..

[8]  David Warde-Farley,et al.  Dynamic modularity in protein interaction networks predicts breast cancer outcome , 2009, Nature Biotechnology.

[9]  S. Licciulli,et al.  The Rac1 splice form Rac1b promotes K-ras-induced lung tumorigenesis , 2012, Oncogene.

[10]  Bridget E. Begg,et al.  A Proteome-Scale Map of the Human Interactome Network , 2014, Cell.

[11]  Hans-Werner Mewes,et al.  CORUM: the comprehensive resource of mammalian protein complexes , 2007, Nucleic Acids Res..

[12]  Amos Bairoch,et al.  ScanProsite: a reference implementation of a PROSITE scanning tool. , 2002, Applied bioinformatics.

[13]  A. Krainer,et al.  The gene encoding the splicing factor SF2/ASF is a proto-oncogene , 2007, Nature Structural &Molecular Biology.

[14]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[15]  Arnaud Céol,et al.  3did: a catalog of domain-based interactions of known three-dimensional structure , 2013, Nucleic Acids Res..

[16]  H. Dvinge,et al.  Widespread intron retention diversifies most cancer transcriptomes , 2015, Genome Medicine.

[17]  Stefan Stamm,et al.  Human tra2-beta1 autoregulates its protein concentration by influencing alternative splicing of its pre-mRNA. , 2004, Human molecular genetics.

[18]  D. Radisky,et al.  Involvement of hnRNP A1 in the matrix metalloprotease‐3‐dependent regulation of Rac1 pre‐mRNA splicing , 2012, Journal of cellular biochemistry.

[19]  Shuying Sun,et al.  SRSF1-Regulated Alternative Splicing in Breast Cancer. , 2015, Molecular cell.

[20]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[21]  J. Cheville,et al.  A p120 Catenin Isoform Switch Affects Rho Activity, Induces Tumor Cell Invasion, and Predicts Metastatic Disease* , 2008, Journal of Biological Chemistry.

[22]  Damian Szklarczyk,et al.  The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored , 2010, Nucleic Acids Res..

[23]  J. Mesirov,et al.  The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.

[24]  Zsuzsanna Dosztányi,et al.  IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content , 2005, Bioinform..

[25]  Hannah H. Chang,et al.  Non-genetic heterogeneity — a mutation-independent driving force for the somatic evolution of tumours , 2009, Nature Reviews Genetics.

[26]  Gael P. Alamancos,et al.  Leveraging transcript quantification for fast computation of alternative splicing profiles , 2014, bioRxiv.

[27]  Gloria M. Sheynkman,et al.  Widespread Expansion of Protein Interaction Capabilities by Alternative Splicing , 2016, Cell.

[28]  Ying Xu,et al.  Structural genomics analysis of alternative splicing and application to isoform structure modeling. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Alex Bateman,et al.  Tissue-Specific Splicing of Disordered Segments that Embed Binding Motifs Rewires Protein Interaction Networks , 2012, Molecular cell.

[30]  S. Miyano,et al.  Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome , 2014, Nature Communications.

[31]  L. Cartegni,et al.  Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic polyA activation. , 2011, Molecular cell.

[32]  K. Brown,et al.  A Transcriptionally Inactive ATF2 Variant Drives Melanomagenesis. , 2016, Cell reports.

[33]  E. Marcotte,et al.  Prioritizing candidate disease genes by network-based boosting of genome-wide association data. , 2011, Genome research.

[34]  J. Yokota,et al.  Development of lung adenocarcinomas with exclusive dependence on oncogene fusions. , 2015, Cancer research.

[35]  Monika Heiner,et al.  The RNA-Binding Protein QKI Suppresses Cancer-Associated Aberrant Splicing , 2014, PLoS genetics.

[36]  David Allman,et al.  Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. , 2015, Cancer discovery.

[37]  Zsuzsanna Dosztányi,et al.  ANCHOR: web server for predicting protein binding regions in disordered proteins , 2009, Bioinform..

[38]  M. Ares,et al.  Context-dependent control of alternative splicing by RNA-binding proteins , 2014, Nature Reviews Genetics.

[39]  Johannes Goll,et al.  A new reference implementation of the PSICQUIC web service , 2013, Nucleic Acids Res..

[40]  Jean-Loup Guillaume,et al.  Fast unfolding of communities in large networks , 2008, 0803.0476.

[41]  Lawrence A. Donehower,et al.  The somatic genomic landscape of chromophobe renal cell carcinoma. , 2014, Cancer cell.

[42]  Yi Xing,et al.  Transcriptome-wide Landscape of Pre-mRNA Alternative Splicing Associated with Metastatic Colonization , 2014, Molecular Cancer Research.

[43]  Nuria Lopez-Bigas,et al.  IntOGen: integration and data mining of multidimensional oncogenomic data , 2010, Nature Methods.

[44]  Eduardo Eyras,et al.  Detection of recurrent alternative splicing switches in tumor samples reveals novel signatures of cancer , 2015, Nucleic acids research.

[45]  Teresa M. Przytycka,et al.  DOMINE: a database of protein domain interactions , 2007, Nucleic Acids Res..

[46]  Chris Sander,et al.  Emerging landscape of oncogenic signatures across human cancers , 2013, Nature Genetics.

[47]  Leonard D. Goldstein,et al.  Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers. , 2016, Cell reports.

[48]  J. Valcárcel,et al.  RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation. , 2013, Molecular cell.

[49]  K. Hansen,et al.  Genome-Wide Identification of Alternative Splice Forms Down-Regulated by Nonsense-Mediated mRNA Decay in Drosophila , 2009, PLoS genetics.

[50]  Arnaud Céol,et al.  3did: a catalog of domain-based interactions of known three-dimensional structure , 2013 .

[51]  Omar Abdel-Wahab,et al.  Therapeutic targeting of splicing in cancer , 2016, Nature Medicine.

[52]  John A. Calarco,et al.  Emerging Roles of Alternative Pre-mRNA Splicing Regulation in Neuronal Development and Function , 2012, Front. Neurosci..

[53]  C. Sander,et al.  Systematic identification of cancer driving signaling pathways based on mutual exclusivity of genomic alterations , 2014, Genome Biology.

[54]  Tom Misteli,et al.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.

[55]  Alexander Lex,et al.  UpSetR: An R Package for the Visualization of Intersecting Sets and their Properties , 2017 .

[56]  Mark Rosenzweig,et al.  Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. , 2015, Cancer discovery.

[57]  Hai Fang,et al.  dcGO: database of domain-centric ontologies on functions, phenotypes, diseases and more , 2012, Nucleic Acids Res..

[58]  E. Eyras,et al.  The prognostic potential of alternative transcript isoforms across human tumors , 2016, Genome Medicine.

[59]  L. Shkreta,et al.  Defective control of pre–messenger RNA splicing in human disease , 2016, The Journal of cell biology.

[60]  Robert D. Finn,et al.  The Pfam protein families database: towards a more sustainable future , 2015, Nucleic Acids Res..

[61]  J. Valcárcel,et al.  Synonymous Mutations Frequently Act as Driver Mutations in Human Cancers , 2014, Cell.

[62]  Michael Q. Zhang,et al.  Differential connectivity of splicing activators and repressors to the human spliceosome , 2015, Genome Biology.

[63]  J. Valcárcel,et al.  Large-scale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer-relevant splicing networks , 2016, Genome research.

[64]  Juan L Trincado,et al.  SUPPA2 provides fast, accurate, and uncertainty-aware differential splicing analysis across multiple conditions , 2017, bioRxiv.

[65]  J. Bourdon,et al.  p53 and its isoforms in cancer , 2007, British Journal of Cancer.

[66]  Abstr Act,et al.  Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma , 2016 .

[67]  Aric Hagberg,et al.  Exploring Network Structure, Dynamics, and Function using NetworkX , 2008, Proceedings of the Python in Science Conference.

[68]  N. Schultz,et al.  Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. , 2015, Cancer discovery.

[69]  Yeon Jeong Kim,et al.  Intron retention is a widespread mechanism of tumor-suppressor inactivation , 2015, Nature Genetics.

[70]  Shinichiro Wachi,et al.  Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues , 2005, Bioinform..

[71]  Xinchen Wang,et al.  Tissue-specific alternative splicing remodels protein-protein interaction networks. , 2012, Molecular cell.

[72]  Robert D. Finn,et al.  iPfam: a database of protein family and domain interactions found in the Protein Data Bank , 2013, Nucleic Acids Res..

[73]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[74]  E. Larsson,et al.  Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types , 2014, Nature Genetics.